NEW BRIEF HIGHLIGHTS THE ECONOMIC COSTS OF PHARMACY BENEFIT MANAGERS
Exploring a tool that millions of Americans use every day when paying for prescription drugs, the Pacific Research Institute today released a new research brief exploring how Pharmacy Benefit Managers (PBMs) impact prescription drug costs, access, and patient care.
“Pharmacy Benefit Managers impact more than 260 million Americans when they purchase their prescription drugs, but most people have no idea what they are, or the big impact they play in their health care,” said Dr. Wayne Winegarden, PRI’s Senior Fellow in Business and Economics and the author of the new issue brief. “Our new brief explores the many ways PBM’s affect prescription drugs, especially the access to, and the costs of, the life-savings medicines they depend upon.”
Winegarden’s new brief, The Economic Costs of Pharmacy Benefit Managers: A Review of the Literature. reviews recent studies on PBMs. Among the key findings:
- PBMs have an undue influence over the medicines that patients can access;
- They provide incentives for higher list prices for medications that come with large rebates and discounts; and
- They trigger higher patient co-pays than necessary given the large discrepancy between list prices and the prices people pay at the counter.
Considering the challenges with PBMs, Winegarden argues that the current system needs more transparency to transform what is currently a bloated and expensive system. The CEO of Express Scripts recently said in an interview with CNBC that Anthem was unlikely to extend its contract with the PBM following its 2019 contract expiration. This follows a $15 billion lawsuit that Anthem filed against Express Scripts in March 2016 alleging that the PBM charged excess prices for drugs.
————————-
Dr. Wayne Winegarden is a Senior Fellow in Business and Economics at Pacific Research Institute. He is also the Principal of Capitol Economic Advisors and a Managing Editor for EconoSTATS.
Click here to see the original article on the PRI website.
Recent Posts
-
SCPC Sends Reasonable & Relevant “Pre-Comment” Letter to CMS
The Senior Care Pharmacy Coalition (SCPC) submitted comments on the Calendar Year 2027 Home Health Prospective Payment System proposed rule, focusing on proposed changes to Medicare enrollment provisions. In its comments, SCPC applauded the work of CMS to address fraud and waste in the system while protecting services for those who need them most. SCPC urged CMS […]
-
SCPC Submits Second Round of Comments to Healthcare Advisory Committee
The Senior Care Pharmacy Coalition submitted comments yesterday to the Healthcare Advisory Committee (HAC). The HAC is a group of experts charged with delivering strategic recommendations directly to the HHS Secretary and CMS Administrator to improve how care is financed and delivered across Medicare, Medicaid and the Children’s Health Insurance Program (CHIP), and the Health […]
-
SCPC Responds to Senate Finance Committee Request for Information on Commonsense Policy Options to Lower Drug Prices for Patients
The Senior Care Pharmacy Coalition (SCPC), the leading voice for the nation’s long-term care (LTC) pharmacy community, submitted comments to the Senate Finance Committee’s Request for Information (RFI) seeking input on commonsense policy options to lower drug prices for patients. “SCPC supports the Committee’s focus on reducing prescription drug costs while preserving beneficiary access and […]
Stay Connected
Get the latest news and updates on issues impacting the long-term care pharmacy community.